Summary of Purpose
This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical management of 25[OH] Vit D levels.Read More →
The following dates are available for this trial. Trial information last updated on 2 June 2017.
|3 Apr 2017||15 Dec 2016||1 Apr 2021||1 Apr 2021||1 May 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Conditions See All
- Heidi T May, PhD, MSPH
- Patti Spencer